9F6C

Cardiac myosin motor domain in the pre-powerstroke state co-crystallized with the inhibitor aficamten

Summary for 9F6C

Entry DOI	10.2210/pdb9f6c/pdb
Descriptor	Myosin-7, SULFATE ION, MAGNESIUM ION, ... (7 entities in total)
Functional Keywords	cardiac myosin, modulator, cardiomyopathy, force production, motor protein
Biological source	Bos taurus (cattle)
Total number of polymer chains	2
Total formula weight	180533.97
Authors	Robert-Paganin, J.,Hartman, J.J.,Morgan, B.P.,Malik, F.I.,Houdusse, A. (deposition date: 2024-05-01, release date: 2024-09-04, Last modification date: 2024-09-11)
Primary citation	Hartman, J.J.,Hwee, D.T.,Robert-Paganin, J.,Chuang, C.,Chin, E.R.,Edell, S.,Lee, K.H.,Madhvani, R.,Paliwal, P.,Pernier, J.,Sarkar, S.S.,Schaletzky, J.,Schauer, K.,Taheri, K.D.,Wang, J.,Wehri, E.,Wu, Y.,Houdusse, A.,Morgan, B.P.,Malik, F.I. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res, 3:1003-1016, 2024 Cited by PubMed: 39196032 DOI: 10.1038/s44161-024-00505-0 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.33 Å)

Structure validation